Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 6/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716207 | 0.92 | BDKRB1 (0.55) | BDKRB1HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL4716396 | 0.91 | BDKRB1 (0.61) | BDKRB1HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL5630639 | 0.91 | BDKRB1 (0.61) | BDKRB1HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL4714381 | 0.90 | BDKRB1 (0.55) | BDKRB1HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL4714835 | 0.88 | BDKRB1 (0.60) | BDKRB1HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL4712523 | 0.87 | BDKRB1 (0.72) | BDKRB1HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL5629162 | 0.84 | BDKRB1 (0.78) | BDKRB1HTR2AHTR2CHTR2B | |
| SCHEMBL5630506 | 0.82 | BDKRB1 (0.61) | BDKRB1 | |
| SCHEMBL4717373 | 0.81 | BDKRB1 (0.53) | BDKRB1HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL5629753 | 0.81 | PARP1 (0.41) | BDKRB1HTR2AHTR2CHTR2BPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | claimed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | BDKRB1 1/4885HTR2A 742/4885HTR2C 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.